Algernon Pharmaceuticals (AGN.c AGNPF) has completed the dosing of the second cohort in its escalating dose Phase 1 clinical study of an IV formulation of DMT.
The purpose of this study is to identify the safety, tolerability and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours, a period which has never been studied clinically.
Plus, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will be recorded.
This is another important step for AGN in its DMT clinical research program as they accelerate into Phase 2 studies to test DMT on patients that have suffered a serious brain injury.
https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/180/algernon-neuroscience-announces-successful-dosing-of-2nd